Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

source : Www.sutrobio.com    save search

2023 American Society of Clinical Oncology (ASCO) Annual Meeting – Presentation
Published: 2023-06-03 (Crawled : 00:20) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

presentation meeting
Sutro Biopharma to Participate in the Jefferies Healthcare Conference
Published: 2023-05-31 (Crawled : 12:01) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 0.22% H: 4.55% C: -2.81%

conference biopharma
2023 American Society of Pediatric Hematology / Oncology (ASPHO) Annual Meeting – Poster
Published: 2023-05-17 (Crawled : 22:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: -1.04% H: 0.18% C: -7.03%

meeting
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
Published: 2023-05-08 (Crawled : 12:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: -0.18% H: 2.56% C: 0.37%

conference life biopharma sciences
Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
Published: 2023-04-27 (Crawled : 21:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: -0.69% H: 1.16% C: -1.39%

biopharma research
2023 American Association for Cancer Research Annual Meeting (AACR) – Poster
Published: 2023-04-18 (Crawled : 18:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 0.21% H: 0.43% C: -3.84%

association cancer research meeting
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
Published: 2023-03-30 (Crawled : 21:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: -0.89% H: 6.31% C: 4.05%

business year biopharma financial
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-03-17 (Crawled : 20:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

nasdaq biopharma grants
13th Annual World ADC London 2023 – Presentation
Published: 2023-03-14 (Crawled : 16:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 1.1% H: 8.01% C: 0.36%

presentation
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
Published: 2023-03-01 (Crawled : 13:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 1.6% H: 3.4% C: 0.7%

biopharma care conference health
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
Published: 2023-02-28 (Crawled : 13:00) - sutrobio.com
ABT | $104.88 0.57% -0.01% 4.7M twitter stocktwits trandingview |
Health Technology
| | O: 0.07% H: 2.58% C: 1.88%
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 5.06% C: -1.57%

biopharma medical
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-02-17 (Crawled : 21:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

biopharma nasdaq grants
BioNova Announces First Patient Dosed in a Phase 1/2 Study of BN301 for the Treatment of Hematologic Malignancies in China
Published: 2023-02-13 (Crawled : 17:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: -0.31% H: 8.62% C: -1.88%

bn301 treatment china study phase 1
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers – Molecular Cancer Therapeutics – AACR Journals
Published: 2023-02-07 (Crawled : 00:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 0.14% H: 0.0% C: -3.99%

stro-002 treatment therapeutics molecular cancer aacr journals
41st Annual JP Morgan Healthcare Conference – Presentation
Published: 2023-01-12 (Crawled : 19:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 5.08% H: 4.22% C: -2.36%

conference presentation
Update on STRO-002 Program and Plans for Registrational Trial in Advanced Ovarian Cancer – Presentation
Published: 2023-01-09 (Crawled : 23:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 1.93% H: 0.89% C: -14.08%

stro-002 program trial presentation update cancer ovarian cancer
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Published: 2023-01-09 (Crawled : 22:00) - sutrobio.com
PCVX S | $53.81 3.94% 3.84% 600K twitter stocktwits trandingview |
Health Technology
| | O: -0.3% H: 1.79% C: 0.35%
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 1.93% H: 0.89% C: -14.08%

stro-002 biopharma update cancer study ovarian cancer phase 1
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-04 (Crawled : 13:00) - sutrobio.com
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 1.37% H: 4.31% C: -0.37%

biopharma conference
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
Published: 2022-12-21 (Crawled : 13:00) - sutrobio.com
PCVX S | $53.81 3.94% 3.84% 600K twitter stocktwits trandingview |
Health Technology
| | O: 0.22% H: 3.45% C: 3.2%
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 4.79% H: 1.43% C: 0.0%

stro-002 biopharma update cancer ovarian cancer
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Published: 2022-12-20 (Crawled : 22:00) - sutrobio.com
PPRUF | $426.544 -2.5% 44.35% 1.5K twitter stocktwits trandingview |
Consumer Non-Durables
| | O: 2.83% H: 2.66% C: -0.36%
PPRUY | $42.85 -0.36% 0.0% 240K twitter stocktwits trandingview |
Manufacturing
| | O: 1.46% H: 1.58% C: 0.82%
PCVX S | $53.81 3.94% 3.84% 600K twitter stocktwits trandingview |
Health Technology
| | O: 0.22% H: 3.45% C: 3.2%
STRO | $2.75 5.36% 5.26% 1M twitter stocktwits trandingview |
Health Technology
| | O: 4.79% H: 1.43% C: 0.0%

biopharma grant agreement
Gainers vs Losers
77% 23%

Top 10 Gainers
ID 4 | $0.077 -9.41% 25.97% 420K twitter stocktwits trandingview |
Finance

BKKT 4 | $1.88 25.33% 14.89% 4.8M twitter stocktwits trandingview |

PHGE | $0.258 -0.39% 8.49% 360K twitter stocktwits trandingview |
Health Technology

MGLD | $1.03 7.77% 14K twitter stocktwits trandingview |
Manufacturing

CZOO | $0.4316 -6.52% 6.7% 65K twitter stocktwits trandingview |

SATX | $0.4226 -1.72% 6.48% 29K twitter stocktwits trandingview |
n/a

CCJ | $45.4 -1.13% 4.6% 3.9M twitter stocktwits trandingview |
Non-Energy Minerals

AUMN | $0.562 0.34% 4.5% 360K twitter stocktwits trandingview |
Non-Energy Minerals

ERJ | $18.69 6.86% 4.33% 2.9M twitter stocktwits trandingview |
Electronic Technology

JBL | $116.91 1.38% 4.3% 2M twitter stocktwits trandingview |
Electronic Technology


Your saved searches
Save your searches and get alerts when important news are released.